Vicore Pharma Trading and Recent Development Update
Vicore Pharma (VICO.ST) closed the 24‑hour period ending at 09:04 AM Central Europe on Friday 23 March 2026 with a 3.73 % increase. The share price stood at SEK 8.88 on major exchanges.
- Shares outstanding: 281.5 million
- Market capitalisation: SEK 246.1 million
- Volume in last 24 h: SEK 6.9 million worth of shares were traded
- Year‑to‑date performance: The share price has fallen 10.62 % since the end of February 2026.
- Moving average: 200‑day simple moving average is SEK 10.78.
- 52‑week range: Highest price recorded on 07 July 2026 at SEK 18.24; lowest price recorded on 10 August 2026 at SEK 8.56.
Latest Company News
Vicore Pharma Holding AB announced that its Phase 2b ASPIRE trial of buloxibutid for idiopathic pulmonary fibrosis has passed a pre‑planned futility analysis. An independent Data Monitoring Committee approved continuation of the study without modification and identified no safety concerns in its review of the available data. The trial enrolled 378 patients across more than 100 sites and is on schedule to report 52‑week topline results in mid‑2027. Company executives stated that the current cash runway extends into the second half of 2028, providing time to plan subsequent development steps. The focus remains on disciplined execution toward database lock and the anticipated readout while maintaining the integrity of the trial data. No quantitative results from the analysis were disclosed.
24‑Hour Performance of Related Stocks
| Stock | 24‑hr Change | Current Price (SEK) | Market Cap (SEK) | P/E Ratio |
|---|---|---|---|---|
| Fagerhult (FAG.ST) | -1.26 % | 17.10 | 290.4 million | 16.64 |
| Qleanair (QAIR.ST) | -3.68 % | 18.25 | 271.9 million | 10.79 |
| Irlab Therapeutics (IRLAB-A.ST) | +0.48 % | 1.93 | 293 million | – |
| Nexam Chemical (NEXAM.ST) | -1.89 % | 2.46 | 266.9 million | – |
| Transtema (TRANS.ST) | -0.64 % | 4.75 | 274.6 million | – |
Company Profile
Vicore Pharma Holding AB is a Swedish pharmaceutical company focused on developing products for anti‑inflammatory, nerve regeneration, and cardiovascular conditions.
